18th Annual World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) is organized by The Metabolic Institute of America (TMIOA). The onsite conference will be held from Dec 03 - 05, 2020 at Hilton Los Angeles/Universal City, Los Angeles, California, United States of America.
Who can attend?
This educational conference is intended for cardiologists, endocrinologists, gastroenterologists, oncologists, internists, diabetologists, OBGYNs, pediatricians, dietitians, nurse practitioners, pharmacists, and any other health care professionals who are interested in improving patients outcome, focusing on insulin resistance, diabetes, obesity, cardiovascular disease, related Kidney and fatty liver morbidity, and potential prevention and management impact on health and society.
The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 18th year, is a unique and exciting multidisciplinary CME program. The Congress is the premiere global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), and energy balance, linking basic research to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.
For nearly two decades, WCIRDC has brought researchers, physicians- clinicians and other healthcare professionals together for a distinctive international program that bridges the latest developments from bench-to-bedside. “I heard it first at the Congress” is a frequent remark from the audience over the years, many of whom attend year after year. Researchers present their latest data and findings on everything from biomarkers to new physiological insights to new ideas for therapies. WCIRDC offers attendees a unique experience to interact in an intimate setting with the distinguished global faculty for a collaborative experience that explores the newest understanding of metabolic diseases and the development of future therapeutic modalities.
Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance (IR), diabetes, and CVD, the Congress’ focus has expanded to cover fat cells, lipids, the kidney, fatty liver, the brain, bone and energy metabolism, inflammation, aging, diet, cancer and more. The Congress addresses dyslipidemia, atherosclerosis, hypertension, and hypercoagulation as well as new pharmaceutical interventions such as incretins, SGLT2i’s, PCSK9i’s and EPA omega 3 to name a few. The goal is to understand the state-of-the-art pathophysiology new medical interventions and to develop appropriate comprehensive clinical management strategies.
For primary care clinicians, Congress will feature a series of workshops and “meet the expert” panels addressing the clinical prevention and management of kidney disease, diabetes, obesity, lipids, the high risk CVD, CHF patient and more. To make basic and clinical research topics relevant to clinical medicine, following the presentations, including basic research, there will be commentaries on clinical implications to practice by recognized global experts. The Congress’ intimate setting promotes personal contacts between participants and the distinguished global faculty wherein everyone learns from the free flow of questions, personal observations and face to face informal discussions.
The Congress attracts state-of-the-art abstracts by young, upcoming and recognized leaders from around the globe. These abstracts will be published in Metabolism: Clinical and Experimental, a peer-reviewed journal published twelve times a year with over 40,000 unique monthly viewers worldwide that is in the top 10% of endocrinology, diabetes, and metabolism journals (https://www.metabolismjournal.com/).
Further, articles about the meeting are published in several medical journals and online medical news sources such as Diabetes Care, Metabolism, The Journal of Diabetes, Endocrine Practice, Diabetes and Vascular Disease Research, Endocrinology Today, Cardiology Today, Endocrine Web, Clinical Endocrinology News, Diabetes in Control, among others.
The program is intended to assess both the clinical and basic science aspects of diabetes, obesity, HTN, dyslipidemia, CHF, CVD, CKD and related cardiometabolic conditions by focusing on insulin resistance, hyperinsulinemia, fat Inflammation and energy metabolism. The goal is to understand the pathophysiology of each condition and develop appropriate comprehensive clinical management plans.
At the conclusion of this session, an attendee will be able to,
• Explain the relationship between diabetes, obesity, and congestive heart failure
• Explain the impact of lipotoxicity and the pathophysiology of CVD
• Examine the role of obesity in the improvement of cardiometabolic conditions
• Describe the purposes of diabetes in the addition of micro & macrovascular conditions: kidney disease, retinopathy, neuropathy, CVD and strokes
• Present complete management of diabetes, through addressing obesity, hypertension, dyslipidemia and hyperglycemia
• Address the role of incretins in the management of diabetes, obesity, and related complications
• Appraise the confirmation supporting the use of SGLT2 inhibitors and GLP1ra's to reduce cardiovascular morbidity & mortality in patients with T2D and established CVD
• Estimate the role of SGLT2i & GLP1ra for primary prevention of cardiovascular morbidity & mortality in patients with T2D
• Note the role of PCSK9 inhibitors in preventing CV morbidity in people with established ASCVD
• Know the relationship between fatty liver disease and diabetes along with CVD
• Explain the pathogenesis of liver and muscle insulin resistance, the role of adipose tissue and of the mitochondria in hyperglycemia and ASCVD
• Assess the influence on the clinical practice of recent CVD, CHF & CKD outcome trials
• Evaluate the impact on the clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes
• Implement best practices for the prevention and management of CHF
• Surmise the Cardiorenal Syndrome
• Review the position of Coagulation and new anti-coagulation agents in the prevention of CVD and CVA
• Discover about diminishing morbidity and mortality by being able to balance the correct medications to the appropriate patients
October 26, 2020
|Registration Type||Last Date||Price|
|General Attendee - Tier Four Fee||02 Dec,2020||USD 650.00|
|Fellow/Resident - Tier Four Fee||02 Dec,2020||USD 400.00|
|Single Day - Regular Fee||02 Dec,2020||USD 250.00|
|Registration Type||End Date||Price|
|General Attendee - Early Fee||01 May,2020||USD 450.00|
|General Attendee - Tier Two Fee||01 Aug,2020||USD 495.00|
|General Attendee - Tier Three Fee||01 Nov,2020||USD 550.00|
|Fellow/Resident - Early Fee||01 May,2020||USD 250.00|
|Fellow/Resident - Tier Two Fee||01 Aug,2020||USD 295.00|
|Fellow/Resident - Tier Three Fee||01 Nov,2020||USD 350.00|
|Medical Student - Early Fee||01 May,2020||USD 175.00|
|Single Day - Early Fee||01 May,2020||USD 200.00|
Hilton Los Angeles/Universal City
555 Universal Hollywood Dr, Universal City
Los Angeles, California, United States of America
Hilton Los Angeles/Universal City,
555 Universal Hollywood Dr, Universal City,
Los Angeles, California, United States of America 91608,
Plan Your Travel
Reviews Given by People
Hotels Near Venue
Subscribe to our Newsletterx
Subscribe to our newsletter and receive updates on medical conferences, board review courses and news